



Post Authorisation Assessments

Baycox 50 mg/ml Oral Suspension

•	19 July 2016	<p>Minor changes to an approved test procedure for an intermediate material used in the manufacturing process of the active substance</p> <p>Minor changes to an approved test procedure for a starting material used in the manufacturing process of the active substance</p> <p>Minor changes to an approved test procedure for a starting material used in the manufacturing process of the active substance</p> <p>Minor changes to an approved test procedure for a starting material used in the manufacturing process of the active substance</p> <p>Minor changes to an approved test procedure for an intermediate material in the manufacturing process of the active substance</p> <p>Other changes to a test procedure for a reagent used in the manufacturing process of the active substance.</p> <p>Tightening of the specification limits for the active substance.</p> <p>Tightening in the specification parameters of an intermediate used in the manufacturing process of the active substance.</p> <p>Change in the specification parameters of an intermediate used in the manufacturing process of the active substance.</p> <p>Deletion of non-significant specification parameters of a starting material used in the manufacturing process of the active substance.</p> <p>Addition of a test procedure for a starting material used in the manufacturing process of the active substance</p> <p>Addition of a test procedure for a starting material used in the manufacturing process of the active substance</p> <p>Replacement of a test procedure for a starting material used in the manufacturing process of the active substance</p>
•	27 May 2016	Delete Unidrug Distribution Group Limited as a distributor.
•	8 December 2015	Addition of a secondary packaging site
•	14 June 2013	Renewal.
•	02 March 2011	To change the distributor.
•	27 October 2009	To update the carton and package leaflet text (dosage instructions) to be consistent with the SPC.

